Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rockwell Medical filings document the company’s hemodialysis-products business, public-company governance, capital-market status, and material-event disclosures. Form 8-K reports cover quarterly and annual operating results, preliminary financial information, corporate presentations furnished under Regulation FD, and product-related business updates incorporated through exhibits.
The company’s proxy materials cover annual meeting matters, director elections, executive compensation, equity awards, and board governance. Other filings disclose common stock registered on the Nasdaq Capital Market, listing-rule compliance notices, and board changes, including director departures, appointments, committee service, and related governance matters.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that SVP and Chief Commercial Officer Timothy Chole received a grant of 85,000 performance-based restricted stock units on May 20, 2025. Each unit relates to one share of common stock and was awarded at no cash cost.
The PSUs have a three-year term ending on the third anniversary of the grant date, with an expiration date of May 20, 2028. They vest on or after the first anniversary only if a stock-price performance hurdle is achieved.
The performance hurdle is met if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days during the three-year performance period equals two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical, Inc. reported that President and CEO Mark Strobeck received a grant of 352,000 performance-based restricted stock units (PSUs) tied to the company’s common stock. The PSUs have a three-year term from the May 20, 2025 grant date and expire on May 20, 2028.
The units vest only if a stock price performance hurdle is achieved. During the three-year performance period, the average closing price over any 60 consecutive trading days must reach two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant date.
Rockwell Medical, Inc. furnished an updated corporate presentation as part of a current report. The presentation, dated March 26, 2026, is attached as Exhibit 99.1 and provides corporate information under Regulation FD.
The company notes this material is furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
Rockwell Medical details its hemodialysis concentrates business, 2025 milestones, and mounting risks in its annual report. The company serves 294 customers, including all five leading U.S. dialysis providers, with dialysate concentrates making up 100% of 2025 revenue and about 88% of sales in the United States.
DaVita accounted for 16% of 2025 net product sales, down from 45% in 2024, after an attempted transition to another supplier. A second amendment extended Rockwell’s DaVita supply agreement through December 31, 2026 with higher pricing. Rockwell ended manufacturing at its South Carolina facility to streamline costs and added 30 new western U.S. customers.
At December 31, 2025, Rockwell reported about $25.0 million in cash, cash equivalents and available-for-sale investments, working capital of $28.6 million, and net cash used in operations of roughly $0.7 million for the year. Management believes capital is sufficient for at least 12 months but warns that additional funding, covenant compliance under its Innovatus term loan, customer concentration, cost inflation, and evolving kidney disease treatments could materially affect future results.
Rockwell Medical, Inc. reported fourth quarter and full-year 2025 results showing a sharp revenue decline but improved margins and positive cash generation. Net sales were $18.3 million in Q4 2025 versus $24.7 million a year earlier, and $69.3 million for 2025 compared with $101.5 million in 2024, mainly due to lower purchase volume from one customer.
Q4 2025 gross margin improved to 21% from 15%, with full-year 2025 gross margin steady at 17%. The company posted a 2025 net loss of $5.3 million versus $0.5 million in 2024, but remained profitable on an Adjusted EBITDA basis at $0.3 million. Cash, cash equivalents and investments were $25.0 million at December 31, 2025, up from $21.6 million. For 2026, Rockwell guides to Adjusted EBITDA of $1 million to $2 million and positive operating cash flow.
ROCKWELL MEDICAL, INC. Chief Operating Officer Heather Hunter reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this withholding, she held 130,079 common shares directly.
ROCKWELL MEDICAL, INC. officer Megan C. Timmins reported a routine tax-related share disposition. On this Form 4, 3,667 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations tied to the vesting of restricted stock units, rather than being sold on the market. After this withholding, Timmins directly holds 162,408 shares of Rockwell Medical common stock.
Rockwell Medical Senior Vice President and CFO Jesse Neri reported a routine tax-related share withholding. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this non-market disposition, Neri directly holds 122,398 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. senior vice president and chief commercial officer Timothy Chole reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. Following this withholding, he directly holds 122,855 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. reported a routine tax-related share disposition by its President and CEO, Mark Strobeck. On the reported date, 7,333 shares of common stock were withheld in connection with the vesting of restricted stock units to cover estimated tax obligations, rather than being sold on the open market. Following this withholding, Strobeck directly owns 323,493 shares of Rockwell Medical common stock.